About This Webinar
A summary of the latest evidence in dementia imaging.
Agenda
  • 15.10-15.40 | 'In Conversation With' Professor Nick Fox
  • 15.40-16.10 | Can we really slow down the progression of Alzheimer's disease? Dr Naji Tabet
  • 16.25-16.55 | Types of dementia - Dr Richard Perry
  • 16.55-17.15 | ROCHE | The utility of ALZ biomarkers in clinical routine - Dr Femke Bouwmann
  • 17.15-18.15 | What will be the impact of Covid-19 on the future of dementia care?
  • 18.15-18.45 | Summary of the latest research in imaging - Professor Clare MacKay
Presenter
  • 1614443722-dd4b898dc846a2cc
    Professor Clare McKay
    Professor of Imaging Neuroscience
    Clare's research focuses on using neuroimaging to understand risk for psychiatric and neurodegenerative disease.

    By the time conditions such as Alzheimer’s Disease and Parkinson’s Disease are clinically diagnosed, much of the damage in the brain is already done. Clare's group focuses on understanding mechanisms of risk, i.e. investigating how factors such as particular genes change brain structure and function before people are suffering from the symptoms of disease. We hope that, when neuroprotective agents become available, we will be able to identify individuals in whom these agents will be most effective.

    Her interest in brain imaging began at the Magnetic Resonance and Image Analysis Research Centre (MARIARC) at the University of Liverpool. She moved to Oxford as a post-doc in 2000, and alongside developing an independent research career she managed the neuroimaging ‘half’ of the Oxford Centre for Clinical Magnetic Resonance Research (OCMR).

    She leads the Translational Neuroimaging Group and is Associate Director of the Oxford Centre for Human Brain Activity (OHBA), which is part of the new Wellcome Centre for Integrative Neuroimaging. She leads the Older Adults & Dementia Theme for the NIHR Oxford Health Biomedical Research Centre, and the Imaging Informatics programme for the MRC Dementias Platform UK. Clare is also imaging lead for the Oxford Parkinson’s Disease Centre (OPDC), and the Whitehall II imaging study.